New Data Shows Diastabol (miglitol) Effective as Both Monotherapy and Combination Therapy in Treatment of Type 2 Diabetes

BRUSSELS,  Belgium,  Oct. 1, 1999--New data presented today at the 35th annual meeting of the European Association for the Study of Diabetes (EASD) demonstrates that the alpha glucosidase inhibitor (AGI) Diastabol (miglitol) significantly improves glycaemic control when combined with other commonly used oral antidiabetic agents, namely metformin (MF) and sulphonylurea (SU) in insufficiently controlled type 2 diabetic patients. Miglitol is currently indicated as monotherapy and in combination with SU.

Two international randomised, double blind, placebo controlled studies evaluated the long term efficacy and safety of miglitol in patients insufficiently controlled by MF or MF & SU.

The first study (1) concluded that miglitol, when added to MF, significantly improves glycaemic control by reducing HbA1c and postprandial glucose levels. This combination was safe and well tolerated. " Miglitol's efficacy in monotherapy or combination with sulphonylurea is well established. This data now clearly demonstrates that miglitol can be safely added to improve glycaemic control in patients insufficiently controlled with metformin alone," explained Professor Maximo Maislos (Soroka University Medical Centre, Ben Gurion University of the Negev, Beer-Sheva, Israel) who presented the study today.

The second study (2) evaluated miglitol's long-term efficacy and safety in patients insufficiently controlled by combined SU and MF. It concluded that miglitol can be safely added to preexisting combination therapy and provides significant additional improvement in glycaemic control.

Professor Eberhard Standl (Schwabing Hospital, Munich, Germany) who presented the second study today, commented: "Many patients with severe Type 2 diabetes are still insufficiently controlled when treated with sulphonylurea and metformin and these patients are likely to benefit from the additional glycaemic control offered by miglitol without increasing the risk of the serious side effects sometimes associated with other therapies" .

Contacts

Press Relations
Tel (33) 1 53 77 4076
Fax (33) 1 53 77 4174

Address
174, avenue de France
75013 Paris
FRANCE

Switchboard
(33) 1 53 77 4000

Posted: June 2004

View comments

Hide
(web3)